MedWatch

Convatec upgrades 2021 sales forecast

In a Q3 trading update, UK-based Convatec has slightly increased its organic revenue growth expectation for the full year. Convatec now thinks revenue growth in the high end of the previously reported interval of 3.5-5 percent is likely.

Photo: Convatec

On Friday morning, UK-based medtech company Convatec, a competitor of Denmark-based Coloplast, released its third quarter report of the year.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Extra data boosts Lundbeck's agitation case

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Related articles

Latest news

See all jobs